Inserting Prevnar 13 Into Adult Treatment Guidelines Could Raise Questions For Practitioners
Executive Summary
Uncertainty about the effect of Pfizer’s vaccine in patients that have already had Merck’s Pneumovax 23 could cause problems.
You may also be interested in...
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.